A K Lipatenkova

Endocrinology Research Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Larisa Dzeranova

Endocrinology Research Center

Ekaterina Pigarova

Endocrinology Research Center

АЭ

А.П. Эктова

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

Liudmila Rozhinskaya

Endocrinology Research Center

АВ

А. В. Кочатков

Clinical Hospital No. 8

Liudmila Astafieva

Burdenko Neurosurgery Institute

ЕА

Е А Пигарова

Endocrinology Research Center

НИ

Н. И. Сазонова

Endocrinology Research Center

ГА

Г. А. Мельниченко

Endocrinology Research Center

ИИ

И. И. Дедов

Endocrinology Research Center

Cooperative Institutions

Endocrinology Research Center

Ministry of Health of the Russian Federation

Burdenko Neurosurgery Institute

Faculdades Guarulhos

Sechenov University

Russian Cancer Research Center NN Blokhin

Federal Almazov North-West Medical Research Centre

Moscow State University of Medicine and Dentistry

Clinical Hospital No. 8

Mental Health Research Center of Russian Academy of Medical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Clinical case: Silent corticotroph pituitary macroadenoma transforming into Cushing disease.

Endocrine Abstracts (2014)

A K Lipatenkova Larisa Dzeranova Ekaterina Pigarova А.П. Эктова

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Corticotropic cell

Cushing's disease

10.1530/endoabs.35.p915

Cite

Citations (2)

Клинический случай: синдром множественной эндокринной неоплазии типа 1 (Мэн 1)

Ожирение и метаболизм (2012)

A K Lipatenkova Larisa Dzeranova Ekaterina Pigarova Л. Я. Рожинская А. В. Кочатков

Multiple endocrine neoplasia syndrome type 1 (MEN1, Wermer syndrome) – group o а heterogeneous inherited deseases, caused by hyperlasia or neoplasia of several endocrine glands. The phenotype of MEN1 is broad, and over 20 different combinations of endocrine and non-endocrine metabolic manifestations have been described. This case demonstrates multiple formations of endocrine organs, starting non-classical with macroprolactonoma resistant to dopamine agonists therapy, other endocrine disorders developed gradually eventually: hyperparathyreoidism and hypoglycemia caused by pancreas lesions, produced proinsulin in high levels.

MEN1

Endocrine gland

Source

Cite

Citations (0)

Гранины в качестве биохимических, иммуногистохимических и метаболических маркеров гормонально-неактивных аденом гипофиза

Ожирение и метаболизм (2013)

A K Lipatenkova Larisa Dzeranova Ekaterina Pigarova

Granins are glycoproteins presented in granules of neuroendocrine cells, they regulate secretory pathway that is responsible for controlled delivery of peptides, hormones and neurotransmitters, and growth factors, organization of the granular matrix, and the mechanisms of administration after hormone secretion The highest accuracy has been observed in neuroendocrine tumors characterized by an intense secretory activity, but its specificity and sensitivity remain very high also in nonfunctioning tumors. The granins application as the markers of nonfunctioning pituitary adenomas would allow the early disease detection, assessment the secretory capacity of tumor, and differential diagnosis with autoimmune forms of pituitary lesions. Furthermore, granins can be used as markers of related metabolic disorders, especially of cardiovascular diseases.

Secretory protein

Source

Cite

Citations (0)

Orlistat improves endothelial function in obese adolescents

Obesity and metabolism (2013)

A K Lipatenkova

Orlistat

10.14341/omet2013443-44

Cite

Citations (0)

Generalized osteoporosis of mixed origin with severe compression fractures and pain syndrome

Obesity and metabolism (2013)

A K Lipatenkova Larisa Dzeranova Е А Пигарова Н. И. Сазонова

He main issue in osteoporosis management is the duration of treatment with different drugs particularly in cases of severe osteoporosis with high fracture risks and indications of switching from one to other agents. Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction and thereby inhibits osteoclast formation, demonstrates significant efficacy for vertebral, nonvertebral and hip fracture risk reduction. This case demonstrates multifactorial reasons for osteoporosis development (postmenopausal osteoporosis, primary hyperparathyroidism), as well as the long-term applying of different osteoporosis drugs with various actions mechanisms and different effectiveness.

Denosumab

10.14341/omet2013432-35

Cite

Citations (0)

Silent pituitary adenomas: review and clinical cases

Obesity and metabolism (2015)

A K Lipatenkova Липатенкова Анна Константиновна Larisa Dzeranova Дзеранова Лариса Константиновна Ekaterina Pigarova

Silent, or clinically nonfunctioning adenomas are morphologically heterogeneous group, characterized by positive immunoreactivity for one or more hormones classically secreted by normal pituitary cells but without clinical expression. Although in some occasions enhanced or changed secretory activity can develop over time. According to immunoreactivity they are divided into "silent" gonado-, cortico-, somato -, mammo – and thyrotropinomas, oncocytomas, «zero-cell» tumors. All types of "silent" adenomas have different biological activity, secretory capacity and outcomes in the postoperative period. This series of clinical cases shows more «aggressiveness», a higher risk of relapse for "silent" cortico- and somatotropinomas. Immunohistochemical analysis of residual tissue can be used to identify patients with high risk of recurrence, to develop optimal treatment and follow-up.

10.14341/omet2015239-46

Cite

Citations (2)

MODERN NEUROENDOCRINOLOGY

Annals of the Russian academy of medical sciences (2012)

И. И. Дедов Г. А. Мельниченко A K Lipatenkova

Neuroendocrinology

10.15690/vramn.v67i8.343

Cite

Citations (4)

Granins as biochemical, immunohistochemical and metabolic markers of nonfunctioning pituitary adenomas

Obesity and metabolism (2013)

A K Lipatenkova Л К Дзеранова Ekaterina Pigarova

Secretory protein

10.14341/2071-8713-4824

Cite

Citations (0)

Effect of fenofibrate on blood pressure reduction

Obesity and metabolism (2013)

A K Lipatenkova

Реферат по материалам статей 1. Gilbert K, Nian H, Yu C, Luther JM, Brown NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens. 2013 Apr;31(4):820-9. doi: 10.1097/HJH.0b013e32835e8227. 2. Kwang K. K. Does Fenofibrate Lower Blood Pressure? Hypertension. 2013 Mar;61(3):e27. doi: 10.1161/HYPERTENSIONAHA.111.00792.

Fenofibrate

10.14341/2071-8713-5076

Cite

Citations (0)

Clinical case: multiple endocrine neoplasia type 1 (MEN 1)

Obesity and metabolism (2012)

A K Lipatenkova Larisa Dzeranova Е А Пигарова Liudmila Rozhinskaya А. В. Кочатков

MEN1

Endocrine gland

10.14341/2071-8713-5129

Cite

Citations (1)